Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tetrodotoxin - WEX Pharmaceuticals

Drug Profile

Tetrodotoxin - WEX Pharmaceuticals

Alternative Names: 9401-TTX; Halneuron; Tectin; Tetrodin; Tocudin

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Medical University; WEX Pharmaceuticals
  • Developer WEX Pharmaceuticals
  • Class Analgesics; Antiarrhythmics; Quinazolines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cancer pain
  • Phase II Neuropathic pain; Pain
  • Suspended Opioid abuse
  • No development reported Anaesthesia

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Pain(In volunteers) in China (Parenteral)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Pain(In volunteers) in USA (Parenteral)
  • 12 Sep 2019 WEX Pharmaceutical plans a pivotal trials for Neuropathic pain in USA and Canada (WEX Pharmaceuticals website - September 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top